Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PHARMACY AND DRUG INDUSTRY LOBBYIST MEETINGS ARE BEING RENEWED

Executive Summary

PHARMACY AND DRUG INDUSTRY LOBBYIST MEETINGS ARE BEING RENEWED in Washington via informal dinner meetings being co-sponsored by trade organizations and individual drug companies. The first two meetings -- held in January and March -- were sponsored by NARD and Merck, and APhA and Lilly. A third session is planned for May to be sponsored by the National Wholesale Druggists' Association and Sterling Winthrop. The meetings include Washington representatives from a number of pharmaceutical firms, pharmacy associations and other health-related organizations. The meetings are apparently intended to provide a forum for discussion of legislative and policy issues among company reps and lobbyists for other segments of the health care industry. The meetings may fill a void left by the disbanding of the Pharmaceutical Industry Washington Advisory Committee (PIWAC). That group was viewed as unnecessary after the Pharmaceutical Manufacturers Association established its Washington Representatives Section in the late 1980s. PIWAC attempted to establish areas of agreement between the diverse groups represented by its members and even recommended policy positions. In forming its Washington Reps Section, PMA apparently decided that a body making recommendations to its board about legislative and regulatory strategy should comprise drug company lobbyists exclusively. The divergence of positions between the industry and pharmacy on policy issues has had a notable effect on the development on many legislative proposals in recent years, such as the outpatient drug benefit in the Medicare Catastrophic Care Act and the Medicaid rebate proposal. Pharmacy support for Sen. Pryor's (D- Ark.) S 2000 drug price legislation was particularly irksome to some representatives of the brandname drug business in Washington.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel